Insider Buying: STAAR Surgical (NASDAQ:STAA) Major Shareholder Purchases 8,200 Shares of Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 8,200 shares of the stock in a transaction dated Wednesday, April 9th. The shares were purchased at an average cost of $15.08 per share, for a total transaction of $123,656.00. Following the transaction, the insider now owns 13,518,591 shares in the company, valued at approximately $203,860,352.28. The trade was a 0.06 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, April 7th, Broadwood Partners, L.P. bought 138,054 shares of STAAR Surgical stock. The shares were purchased at an average cost of $15.61 per share, for a total transaction of $2,155,022.94.
• On Friday, April 4th, Broadwood Partners, L.P. purchased 497,631 shares of STAAR Surgical stock. The stock was purchased at an average cost of $15.91 per share, with a total value of $7,917,309.21.
• On Wednesday, April 2nd, Broadwood Partners, L.P. purchased 31,780 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.43 per share, for a total transaction of $553,925.40.
• On Monday, March 31st, Broadwood Partners, L.P. acquired 22,189 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.46 per share, with a total value of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. bought 3,620 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.48 per share, for a total transaction of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. purchased 34,296 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. acquired 108,720 shares of STAAR Surgical stock. The stock was bought at an average price of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. bought 93,124 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. purchased 249,503 shares of STAAR Surgical stock. The stock was bought at an average cost of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. acquired 259,316 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.05 per share, with a total value of $4,421,337.80.

STAAR Surgical Stock Performance

STAA stock opened at $16.79 on Friday. The company’s 50 day moving average price is $17.66 and its 200 day moving average price is $24.00. The firm has a market capitalization of $828.17 million, a price-to-earnings ratio of -40.95 and a beta of 0.75. STAAR Surgical has a fifty-two week low of $13.50 and a fifty-two week high of $51.34.

Institutional Investors Weigh In On STAAR Surgical

Large investors have recently modified their holdings of the company. Quarry LP purchased a new stake in shares of STAAR Surgical during the 3rd quarter worth $50,000. KLP Kapitalforvaltning AS acquired a new stake in STAAR Surgical in the fourth quarter valued at $180,000. GAMMA Investing LLC lifted its holdings in STAAR Surgical by 4,086.0% during the 1st quarter. GAMMA Investing LLC now owns 14,651 shares of the medical instruments supplier’s stock worth $258,000 after buying an additional 14,301 shares during the last quarter. Bridgefront Capital LLC boosted its position in shares of STAAR Surgical by 27.2% during the 4th quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock worth $262,000 after acquiring an additional 2,306 shares in the last quarter. Finally, FMR LLC boosted its position in shares of STAAR Surgical by 79.3% during the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock worth $263,000 after acquiring an additional 3,136 shares in the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on STAA. Stifel Nicolaus decreased their price target on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. Jefferies Financial Group lowered STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Stephens reaffirmed an “equal weight” rating and issued a $17.00 target price on shares of STAAR Surgical in a research report on Tuesday, March 18th. William Blair cut shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 12th. Finally, Canaccord Genuity Group lowered their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $25.29.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.